Diagnostic Approach for Pyoderma Gangrenosum

Diagnostic Criteria

Pyoderma gangrenosum is primarily a diagnosis of exclusion that requires ruling out other possible skin diseases, such as ecthyma, necrotizing vasculitis, arterial or venous insufficiency ulceration, according to the European Crohn's and Colitis Organisation 1
The diagnosis is typically made clinically based on the characteristic appearance of lesions, including deep excavating ulcerations with purulent material that is sterile on culture unless secondary infection has occurred, as recommended by the European Crohn's and Colitis Organisation 1
Biopsy from the periphery of the lesion can help exclude other disorders, but findings in pyoderma gangrenosum are non-specific, as noted by the European Crohn's and Colitis Organisation 1

Misdiagnosis of pyoderma gangrenosum can occur in a substantial percentage of cases due to its variable presentation, with a high recurrence rate of more than 25% of cases, often in the same location as the initial episode, according to the European Crohn's and Colitis Organisation and other guidelines 1, 2
The therapeutic goal should be rapid healing as pyoderma gangrenosum can be a debilitating skin disorder, with first-line treatment typically involving systemic corticosteroids, as recommended by the European Crohn's and Colitis Organisation 1, 2

Infliximab or adalimumab are effective second-line options, particularly when rapid response to corticosteroids is not achieved, according to the European Crohn's and Colitis Organisation 1, 2
Topical calcineurin inhibitors can be used for smaller lesions, as suggested by guidelines from the European Crohn's and Colitis Organisation and other organisations 2

The European Crohn's and Colitis Organisation recommends considering pyoderma gangrenosum in patients with rapidly developing, painful skin ulcers, particularly those with a history of inflammatory bowel disease or other systemic disorders 3
Biopsy from the periphery of the lesion is recommended in atypical cases to exclude other disorders, according to the Journal of Crohn's and Colitis 3

The American Gastroenterological Association suggests that 50-70% of pyoderma gangrenosum cases are associated with underlying systemic disorders, making comprehensive screening essential, although the exact percentage is not specified in the provided reference 3

The classic (ulcerative) type of pyoderma gangrenosum is characterized by deep excavating ulcerations containing purulent material that is sterile on culture unless secondary infection has occurred, commonly affecting the shins and areas adjacent to stomas, and initially presents as single or multiple erythematous papules or pustules, followed by dermal necrosis, with lesions often preceded by trauma through a phenomenon called pathergy, in patients with inflammatory bowel disease or other systemic disorders 4
The peristomal type of pyoderma gangrenosum occurs specifically around stomas, and closure of the stoma may lead to resolution of lesions, highlighting the importance of considering pyoderma gangrenosum in patients with stomas 4

Inflammatory bowel disease is associated with pyoderma gangrenosum, occurring in 0.6-2.1% of ulcerative colitis patients, emphasizing the need for comprehensive screening for underlying systemic disorders 4